 BOSTON, Nov. 07, 2022 GLOBE NEWSWIRE -- Cue Biopharma, Inc. Nasdaq: CUE, a clinical-stage biopharmaceutical company developing a novel class of injectable biologics to selectively engage and modulate tumor-specific T cells directly within the patients body, announced today that it will host a conference call and webcast to provide a business update on Monday, November 14, 2022 at 4:30 p.m. EST. Live and archived versions of the event can be accessed via the Companys website. 